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Abstract
Over recent years, the research community has been increasingly using preprint servers to share manuscripts that are
not yet peer-reviewed. Even if it enables quick dissemination of research findings, this practice raises several challenges in publication ethics and integrity. In particular, preprints have become an important source of information
for stakeholders interested in COVID19 research developments, including traditional media, social media, and policy
makers. Despite caveats about their nature, many users can still confuse pre-prints with peer-reviewed manuscripts. If
unconfirmed but already widely shared first-draft results later prove wrong or misinterpreted, it can be very difficult to
“unlearn” what we thought was true. Complexity further increases if unconfirmed findings have been used to inform
guidelines. To help achieve a balance between early access to research findings and its negative consequences, we
formulated five recommendations: (a) consensus should be sought on a term clearer than ‘pre-print’, such as ‘Unrefereed manuscript’, “Manuscript awaiting peer review” or ‘’Non-reviewed manuscript”; (b) Caveats about unrefereed
manuscripts should be prominent on their first page, and each page should include a red watermark stating ‘Caution—Not Peer Reviewed’; (c) pre-print authors should certify that their manuscript will be submitted to a peer-review
journal, and should regularly update the manuscript status; (d) high level consultations should be convened, to
formulate clear principles and policies for the publication and dissemination of non-peer reviewed research results;
(e) in the longer term, an international initiative to certify servers that comply with good practices could be envisaged.
Background
Over recent years, the research community has been
increasingly using preprint servers to share manuscripts
that have not yet been peer-reviewed, enabling quick dissemination of research findings, and in some cases to
obtain peer feedback to improve the final version submitted to a journal [1]. Relevant international stakeholders provide guidance on ethics and integrity in scientific
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publications, in particular the Committee on Publication Ethics (COPE) and the International Committee of
Medical Journal Editors (ICMJE). However, issues related
to publication ethics and integrity become more complicated, when a form of publication has already occurred
before peer review and is available to the public. Furthermore, calls to rapidly share research results to
inform public health emergencies including COVID19,
have introduced additional layers of complexity [2–4].
For instance, according to the World Health Organization (WHO) Working Group on Ethics and COVID19,
researchers generating information with the potential to
aid response efforts have an ethical obligation to share
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it “without waiting for publication in scientific journals”,
and as soon as the information “is quality-controlled for
release (e.g., peer-reviewed)” [5]. These recommendations have an inherent conflict, as the quality control of
the peer-review process is managed by the scientific journals whose publication timelines should not be waited
for. The pursuit of rapid dissemination also comes into
conflict with the need to comply with adequate publication standards [2].
Preprint platforms: benefits and risks

Preprints (i.e. preliminary reports of work not yet subject
to peer review) are increasingly posted online on websites such as the well-known MedRxiv, arXiv and bioRxiv
[6–8], as well as other servers. These can be valuable
mechanisms to facilitate rapid communication within
the international scientific community, and trigger early,
fruitful and transparent discussion among peers, while
waiting for the scientific work to undergo a journal’s
peer review. A cross-sectional study of preprint policies
among the 100 clinical journals with the highest impact
factors showed that 86% of journals allow for submitted articles to be previously posted as preprints, making
researchers less concerned that posting a manuscript on a
preprint server will disqualify it from further publication
[1]. However, it remains important to thoroughly understand and accurately describe the nature and purpose of
preprints. This is why arXiv explicitly states that material is “not peer-reviewed by arXiv” and” they should not
be relied upon without context to guide clinical practice
or health-related behavior and should not be reported
in news media as established information without consulting multiple experts in the field” [7]; and bioRxiv
clarifies that “articles are not peer-reviewed, edited, or
typeset before being posted online” [8]. Preprints posted
in MedRxiv, arXiv and bioRxiv include a small header or
footer on each page with a warning that the article has
not undergone peer review [6–8]. MedRxiv also explicitly states that due to the inherent nature of “preliminary reports of work that have not been certified by peer
review”, preprints “should not be relied on to guide clinical practice or health-related behavior and should not be
reported in news media as established information” [6].
This is an important caveat as there is no assurance that
preprints have not had any external quality control when
they are made publicly available. However, it is unlikely
that it will always be carefully read—for instance, when
preprints are circulated via social media.
Though peer review remains the de facto source of
quality-assurance in scientific publishing [9], it does
not always prevent inaccurate reports from entering
the scientific literature [10–12], and mechanisms to
ensure reviewer access to original data sets or codes for
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analysis to strengthen the quality of review are not systematically in place. This has become particularly evident during the pandemic. Smith and colleagues noted
in March 2021 that in a rush to disseminate information
about COVID19, diverse inaccuracies have been published, causing inappropriate changes in clinical care,
ineffective public health responses, and increasing anxiety in communities [13]. It is also likely that the rush to
publish COVID19 manuscripts is causing shortages of
qualified reviewers. The vast and growing volume of submissions related to COVID19 is precipitating reviewer
fatigue. Despite the limitations, peer review can help to
mitigate overinterpretation and misreporting of results,
and reduce the proportion of poor-quality and inaccurate publications [11–13]. Therefore, when it comes to
pre-prints, both authors and readers would benefit from
guidance about their appropriate dissemination and
interpretation, and on reliable servers for posting and
finding preprints.
The WHO has established a platform bringing together
approved clinical trial registries [14], and a similar initiative for pre-print servers may be necessary. The Committee on Publication Ethics (COPE) and the International
Committee of Medical Journal Editors (ICMJE) could
play an essential role in setting high ethical standards for
reporting and disseminating research findings—including those that have not yet been peer-reviewed-, intending to promote integrity along all phases of research
dissemination.
Preprints: what’s in a name

Despite the caveats provided in various servers, preprints
can still be confused with peer-reviewed manuscripts.
The name “pre-print” itself may further encourage misunderstanding. The term implies that the manuscript will
be printed or published, thus inferring a level of quality
sufficient for publication. It may also raise expectations
that the manuscript should, or ever will in any case be
printed. Additionally, “pre-print” sounds very close to
“Epub ahead of print", which indicates a peer-reviewed
article that is being listed electronically before being
typeset [15].
For some users, especially those who are not involved
in the scientific publishing process, such as journalists,
politicians, policy-makers, and the general public, this
language implicitly suggests a sort of imprimatur, i.e.
that the contents have already be approved, which may
increase the probability that they are widely promoted
and disseminated before a robust external evaluation. A
clearer term should be chosen instead of ‘preprint’, such
as ‘Unrefereed manuscript’ or “Manuscript awaiting peer
review” or ‘’Non-reviewed manuscript”, to avoid preventable misunderstandings.
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Hunger for scientific information in times of COVID19

The COVID19 pandemic has created a global “hunger”
for scientific information to inform policy and the general public. In the 5 months prior to the COVID19 era
(1/8/2019 to 31/12/2019), 14,078 preprints were posted
in MedRxiv and bioRxiv. This number increased by
61.2% to 22,691 in the first 5-months of the COVID19
era (1/1/2020 to 31/5/2020), including both COVID19
and non-COVID19-related preprints. Preprints have
become an important source of information for a variety
of stakeholders interested in COVID19 research developments, including traditional media, social media, and
policy-makers. But the philosophy of preprints, i.e. that
errors will get fixed over time as the scientific community crowdsources and opines on the findings [22], may
be unknown to or misunderstood by many of their new
users, including politicians, journalists, “influencers”, prescribers, policy-makers—and sometimes even researchers. Nowadays, research appraisal and synthesis often
occur before a decision is reached on publication, with
the risk of leading to “irresponsible dissemination, as
flawed studies are picked up by the media” [2]. For example, suppose clinical trial findings are only available as
preprints. In that case, a cautionary approach should be
taken to the interpretation of their findings, which should
not be used as the sole basis for introducing a new therapeutic or preventive intervention into practice and policy.
Lack of caution may have been a factor in the publication and withdrawal of early evidence on hydroxychloroquine efficacy in COVID19 [16–20]. Numerous papers
related to COVID19 cite preprint materials, and it is not
always explicitly stated that these are not peer-reviewed
and should be cautiously and critically interpreted [21].
Additionally, if unconfirmed but widely shared firstdraft results later prove to be wrong or misinterpreted,
it can be very difficult for people to “unlearn” what they
thought was true [22], because of ‘anchoring bias’, which
comes into play when individuals prioritize information and data that support their initial impressions, even
when first impressions are wrong [23]. Complexity may
further increase if such unconfirmed findings had been
used to inform guidelines; and if pre-prints remain preprints indefinitely and never get formally published,
either because they are rejected or not even submitted.
We need a balance between early access to research
findings and its unwanted negative consequences, such
as the rushed adoption of policies unsupported by evidence on efficacy and safety, and misplaced or unrealistic expectations from the public, policy-makers and
stakeholders [16, 24–27]. Therefore, we contend that all
preprint servers should state, as does MedRxiv [6], that
“Preprints are preliminary reports of work that have not
been certified by peer review. They should not be relied
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on to guide clinical practice or health-related behaviour
and should not be reported in news media as established
information”. The caveat should not be divorced from
preprints when they circulate, thus this statement should
be prominent on the first page of each preprint, and each
page should include a red watermark stating ‘Caution—
Not Peer-Reviewed’ [10, 15]. This call is in line with a
statement from the Editors of The Lancet, who confirmed the journal policy to make preprints a permanent
offering, while applying “a more obvious watermark stating that these are preprints and not peer-reviewed” [28].
A call for scientific integrity standards

While preprints can help to make new evidence-based
knowledge rapidly available to the scientific community, and perhaps improve scientific transparency [15],
these benefits can be undermined by harms caused by
the release, dissemination, and misuse of unreliable evidence. It is not a foregone conclusion that the potential
benefits of preprints always outweigh the risks of harm
[10, 29]. It is also crucial that preprints are accompanied
by a minimal set of essential, ethics-related information.
However, this is not always the case. For instance, only
two-thirds of research paper authors who submitted to
the Lancet Group journals and opted to post pre-prints
at submission, had posted all this information, i.e. ethics approval if needed, declaration of interests, funding
statement, and prospective registration for randomised
controlled trials [28]. Thus, the various stakeholders
that currently encourage the use of ‘preprints’, including
research institutions and research funding agencies [30],
should also encourage improvement of ethical standards,
appropriate terminology, warnings regarding interpretation and dissemination, and recognition of limitations.
Given the rapid and growing importance and use of preprint servers, particularly concerning the ongoing pandemic, the time is ripe for the scientific community to
agree on “Good Preprint Practices” formally. Adequate
and harmonized scientific quality and integrity standards
[10] should be defined, as they have been for other critical research and reporting activities [31], and appropriate mechanisms for implementation and enforcement
of such good practices should be identified and implemented. In particular, we propose the following specific
recommendations:
• As the term “preprint” may cause misunderstanding
about the nature of these manuscripts, consensus
should be urgently sought on a clearer term, such
as ‘Unrefereed manuscript’ or “Manuscript awaiting
peer review” or ‘’Non-reviewed manuscript”.
• Key caveats about unrefereed manuscripts (i.e., that
they are preliminary reports of work that have not
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been subject to peer review; that they should not be
relied on to guide clinical practice or health-related
behaviour; and that they should not be reported in
news media as established information), should be
prominent on the first page of each preprint, and
each page should include a red watermark stating
‘Caution—Not Peer Reviewed’.
• Pre-print servers should require authors to certify
that the manuscript will imminently be -or is- submitted to a peer review journal; to regularly update
the status of the manuscript (e.g. submitted, rejected,
re-submitted, published with DOI); and to disclose
their pre-print history.
• High level consultations should be convened with
relevant stakeholders, including but not limited to
the ICMJE, COPE and WHO, to formulate clear
principles and policies for the publication and dissemination of non peer-reviewed research results,
and to further disseminate such principles and policies to the scientific community.
• In the longer term, an initiative to certify servers that
comply with agreed good practices could be envisaged.
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